These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10893006)

  • 21. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance.
    Vecchi M; Sinico A; Bianchi MB; Radice A; Gionchetti P; Campieri M; de Franchis R
    Scand J Gastroenterol; 1998 Dec; 33(12):1284-8. PubMed ID: 9930392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissociation of systemic and mucosal autoimmunity in cystic fibrosis.
    Theprungsirikul J; Skopelja-Gardner S; Meagher RE; Clancy JP; Zemanick ET; Ashare A; Rigby WFC
    J Cyst Fibros; 2020 Mar; 19(2):196-202. PubMed ID: 31262645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK).
    Lindgren S; Nilsson S; Nässberger L; Verbaan H; Wieslander J
    J Gastroenterol Hepatol; 2000 Apr; 15(4):437-42. PubMed ID: 10824890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.
    Schultz H; Weiss J; Carroll SF; Gross WL
    J Leukoc Biol; 2001 Apr; 69(4):505-12. PubMed ID: 11310835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
    Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
    Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BPI-ANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule.
    Schultz H; Csernok E; Nikkari S; Toivanen P; Toivanen A; Gross WL
    Scand J Rheumatol; 2000; 29(4):226-31. PubMed ID: 11028843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
    Cooper T; Savige J; Nassis L; Paspaliaris B; Neeson P; Neil J; Knight KR; Daskalakis M; Doery JC
    Rheumatol Int; 2000; 19(4):129-36. PubMed ID: 10836522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement.
    Wada Y; Kuroda T; Murasawa A; Nakano M; Narita I
    Mod Rheumatol; 2010 Jun; 20(3):252-6. PubMed ID: 20107854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis.
    Xin G; Zhao MH; Wang HY
    Clin Diagn Lab Immunol; 2004 May; 11(3):559-62. PubMed ID: 15138182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease.
    Yang JJ; Tuttle R; Falk RJ; Jennette JC
    Clin Exp Immunol; 1996 Jul; 105(1):125-31. PubMed ID: 8697620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
    Khanna D; Aggarwal A; Bhakuni DS; Dayal R; Misra R
    J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
    Zhao MH; Jones SJ; Lockwood CM
    Clin Exp Immunol; 1995 Jan; 99(1):49-56. PubMed ID: 7813109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations.
    Manolova I; Dancheva M; Halacheva K
    Rheumatol Int; 2001 Jul; 20(5):197-204. PubMed ID: 11518040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
    Rotschild M; Elias N; Berkowitz D; Pollak S; Shinawi M; Beck R; Bentur L
    Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
    Schinke S; Fellermann K; Herlyn K; Reichel PH; Fundke R; Stange EF; Gross WL; Schultz H
    Inflamm Bowel Dis; 2004 Nov; 10(6):763-70. PubMed ID: 15626895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations.
    Schultz H; Csernok E; Herlyn K; Reichel PH; Moosig F; Cornely OA; Fagerhol MK; Gross WL
    Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S117-20. PubMed ID: 14740437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antineutrophil cytoplasm autoantibodies in patients with tuberculosis are directed against bactericidal/permeability increasing protein and are detected after treatment initiation.
    Esquivel-Valerio JA; Flores-Suárez LF; Rodríguez-Amado J; Garza-Elizondo MA; Rendón A; Salinas-Carmona MC
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):35-9. PubMed ID: 20412700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antineutrophil cytoplasmic antibodies in children.
    Sedivá A; Kolárová I; Bartůnková J
    Eur J Pediatr; 1998 Dec; 157(12):987-91. PubMed ID: 9877037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization.
    Tian Y; Zeng T; Tan L; Wu Y; Yu J; Huang J; Pei Z
    J Clin Lab Anal; 2019 Jul; 33(6):e22908. PubMed ID: 31106488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI).
    Brownlee AA; Lockwood CM
    Clin Exp Immunol; 1999 Jul; 117(1):183-9. PubMed ID: 10403934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.